The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Larm om vaccinbrist efter utbrott av difteri i Västafrika

Ett allvarligt utbrott av difteri har drabbat Västafrika. Nu varnar Läkare utan gränser för brist på läkemedel och vaccin mot sjukdomen.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.

Nygammal vd åter på Hamlet Biopharma

Hamlet Biopharma har utsett Martin Erixon till tillförordnad verkställande direktör.

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says in an interview about his career and potential future blockbusters.

Ny vd för AOP Orphan Pharmaceuticals

AOP Orphan Pharmaceuticals har utsett Sofia Opitz till ny vd. Hon kommer närmast från en tjänst som Country Manager för Sverige, Norge och Danmark på företaget Biocodex.

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that aimed to find answers and solutions to this downward trend. One of the proposals was a stable, sustainable and funded model for collaboration.

Fetmaläkemedlet Wegovy minskade risk för hjärt-kärlsjukdom i stor studie

Enligt resultat från en studie med över 17 000 patienter medförde användning av det omtalade fetmaläkemedlet Wegovy en signifikant minskad risk för hjärt-kärlsjukdom. Resultaten gör att Novo Nordisk nu är ett av världens högst värderade företag.

Förlikning i babypuderskandal stoppas av domstol

Det amerikanska läkemedelsbolaget Johnson & Johnson har för en andra gång fått avslag av en domare om en konkursansökan för dotterbolaget LTL Management, mest känt som enheten bakom det omtalade babypudret som misstänkts ha orsakat cancer i en rad fall.

Astra Zeneca får ny Nordenchef

AstraZeneca moves to brewery quarters in central Copenhagen

AstraZeneca in Denmark is moving its business into central Copenhagen and the old brewery quarters in Carlsberg Byen.

This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish government are splitting the costs of the project, which is expected to produce new treatments

Egetis lägger ned buddiskussionerna

Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

A new malaria vaccine offers hope but much more research is still needed

There has long been no vaccine against malaria, but there have been breakthroughs in recent years. However, it is still unclear how we become immune to the malaria parasite, and this is a vital piece of the puzzle for creating effective vaccines, says malaria researcher Kristina Persson.

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

Han blir ny nordisk chef på Becton Dickinson

Det amerikanska medicinteknikbolaget Becton Dickinson and Company (BD) har anställt en ny nordisk chef, Hans Braunstein.

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Science Sweden has talked to some of those that attended the conference.

Egetis bekräftar budsamtal

Den svenska läkemedelsutvecklaren Egetis Therapeutics för diskussioner om ett potentiellt bud på bolaget. Det bekräftar företaget i en kommentar till ihärdiga rykten på marknaden.

Sobis giktläkemedel nådde primära mål i fas III

Svenska Sobi och amerikanska partnern Selecta rapporterar övergripande resultat från fas III-studier med giktläkemedlet SEL-212.

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju miljarder dollar år 2030, enligt det japanska läkemedelsbolaget Eisai.